Changes in the management group
Today, Episurf Medical (NASDAQ: EPIS B) announces that after almost 9 years as Chief Operating Officer at Episurf Medical, Jeanette Spångberg has decided to accept a position outside of Episurf Medical. “Jeanette has been instrumental in the development of the Episealer® technology and she has been a much appreciated manager and colleague. We wish Jeanette all the best for the future, and I would like to thank Jeanette for her contribution to Episurf” says Pål Ryfors, CEO Episurf Medical.
Episurf Medical also announces that Katarina Flodström, currently Chief Regulatory Officer – Regulatory Affairs, Quality and IP, is appointed as Chief Operating Officer. “I have been working closely with Katarina during the last years, and I am very pleased that Katarina has chosen to assume the position as COO. Katarina has been working with the Episealer® technology in various capacities for a long time, and during the last two years, she has had an extra focus towards our US-project, something that we put a great deal of value on” continues Pål Ryfors.
In conjunction to these changes, Episurf Medical announces that Michael Näsström is appointed Acting Quality Manager. Michael Näsström is today working in the Company’s quality department.
These changes take effect on June 1st 2019.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CEST on 5 April 2019.